• Join our community!

    Do you have questions about celiac disease or the gluten-free diet?

  • Ads by Google:
     




    Get email alerts Subscribe to Celiac.com's FREE weekly eNewsletter

    Ads by Google:



       Get email alertsSubscribe to Celiac.com's FREE weekly eNewsletter

  • Member Statistics

    77,267
    Total Members
    3,093
    Most Online
    Lindita
    Newest Member
    Lindita
    Joined
  • 0

    Mom Hits Home-run with Gluten-free Bread


    Jefferson Adams

    Celiac.com 12/10/2009 - A UK mother-turned-entrepreneur is about to notch the one-million loaf sales mark for the gluten-free bread she invented to help her sons’ food allergies.  Launched by Lucinda Bruce-Gardyne in April, Genius bread originally made its debut exclusively at British supermarket giant Tesco, which had just debuted its "Free From" line of products.


    Ads by Google:




    ARTICLE CONTINUES BELOW ADS
    Ads by Google:



    Genius has expanded to other retailers, including Asda and Waitrose, and will make its way into Sainsbury’s in the new year.  Also available in Ireland, Genius is eyeing plans to launch in a number of overseas markets. The bread has "just taken off,” she said.

    Bruce-Gardyne, who previously worked at top London restaurant Bibendum and has written recipe books for food allergy sufferers, began developing her gluten-free bread three years ago, after finding existing products to be lacking in quality. “They were packed with stabilizers and preservatives,” she said.

    Mom Hits Home-run with Gluten-free BreadWorking from her home kitchen in Edinburgh, Bruce-Gardyne spent several hours a day crafting her recipe for bread that looked and tasted like regular, commercial gluten-containing bread. Her effort was not without its challenges. She was "baking constantly," she says, and “I broke my oven twice because of overuse,” she said.

    She teamed up with United Central Bakeries, a specialty industrial baking company, at an early stage of development, and the company now bakes all the bread sold under the Genius brand. She also has the good fortune to have support from Sir Bill Gammell, the boss of Cairn Energy, who suffers from gluten intolerance. Their children attend the same school, and the two met after Sir Bill sampled the former chef’s bread. He has become keen to help commercialize it.

    To date, the business has attracted investment of between $1.6 million and $3.3m and sales are running at about $4 million.  Genius sells an average 45,000 loaves a week at about $4 each. Bruce-Gardyne is optimistic about the company's future. Genius is looking to diversify: “We have 18 new products coming out including pre-sliced bread, rolls and ciabatta” said Bruce-Gardyne. She is also working on a gluten-free croissant. “Nothing will be launched unless it tastes as good or better than the mainstream alternative."

    Will Genius bread make it to America? Stay tuned…

    More: Times Online

    0


    User Feedback

    Recommended Comments

    Very interesting - hope her breads do come to America.

    Share this comment


    Link to comment
    Share on other sites

    Is there wheat starch in it? They often use codex wheat starch in the U.k and Scandinavia especially for bread.

    Share this comment


    Link to comment
    Share on other sites
    Guest Hatlover

    Posted

    I have eaten this bread and it is indeed "genius"! Quite soft and chewy like wheat bread, not the cakey texture of a lot of gluten-free bread, and it makes especially great toast. There is no wheat in it whatsoever, it uses potato, tapioca and rice flours.

    Share this comment


    Link to comment
    Share on other sites

    As an expat living in the UK, I too have eaten Genius bread which is very good. Since I will be returning to the US soon I am hopeful that it will arrive in America as well. Gluten-free foods in the UK are much more advanced than in the US.

    Share this comment


    Link to comment
    Share on other sites


    Your content will need to be approved by a moderator

    Guest
    You are commenting as a guest. If you have an account, please sign in.
    Add a comment...

    ×   Pasted as rich text.   Paste as plain text instead

      Only 75 emoji are allowed.

    ×   Your link has been automatically embedded.   Display as a link instead

    ×   Your previous content has been restored.   Clear editor

    ×   You cannot paste images directly. Upload or insert images from URL.


  • Popular Contributors

  • Ads by Google:

  • Who's Online   8 Members, 0 Anonymous, 1,010 Guests (See full list)

  • Related Articles

    Destiny Stone
    Celiac.com 02/12/2010 - A recent study to research thepredominance of celiac disease in healthy school children in IrbidCity, Jordan was conducted using ELISA, a common serological test forthe presence of EmA antibodies which are associated with celiacdisease.
    Serum samplesfrom the children were analyzed for the presence of IgA anti-tissuetransglutaminase antibodies (tTG). Samples that tested positive fortTG, were then analyzed for IgA anti-endomysium antibodies (EmA).Positive EmA results indicated the presence of celiac in thechildren.
    Using 868 boys &1,117 girls ages 5.5 to 9.5, the study measured the positiveserology of the children's weight and height, Body Mass Index (BMI)as well as blood samples from the children to determine theprevalence of celiac disease.
    The researchers found that 16 of the 1,985 children tested, had positive EmAantibodies, and were also positive for celiac disease. The resultsfurther indicated that both boys and girls with positive EmAantibodies also showed significant height reduction compared tochildren without the presence of the antibodies. However, only boyswith positive antibodies showed significant weight reduction.
    The studyconfirmed that celiac disease is widespread among Jordanschool children. It also concluded that children with celiac diseaseare prone to lower height, weight and BMI compared to children withnegative EmA antibody results.


    Sources:
    http://7thspace.com/headlines/334475/serological_screening_for_celiac_disease_in_schoolchildren_in_jordan_is_height_and_weight_affected_when_seropositive.html





    Jefferson Adams
    Celiac.com 11/25/2013 - More and more professional athletes are claiming to reap benefits from adopting a gluten-free diet. What’s the science behind these claims?
    Writing for the Washington Post, Anna Medaris Miller has a very solid article in which she investigates the science behind the claims by many professional athletes that they has reaped tremendous physical benefits by adopting a gluten-free diet.
    Miller cites the growing popularity of gluten-free foods in general, as well as the move away from carbs by many professional athletes. She notes that New Orleans Saints quarterback Drew Brees, the Garmin cycling team and top tennis players Andy Roddick and Novak Djokovic have all been vocal about the benefits of gluten-free diets.
    Still, a gluten-free diet won’t turn you into an Olympic athlete, Fasano says. “But when you go to the high-level performing athletes in which a fraction of a second can mean the difference between winning and losing an event, or be[ing] able to complete a marathon or not within a certain time frame, that can be the small edge that helps you.”
    Some researchers theorize that eliminating gluten allows the body to better carry oxygen to the muscles, which may boost athletic performance.
    There are other theories as to why some athletes report improved athletic performance after eliminating gluten.
    So far, performance claims attributed to a gluten-free diet are purely anecdotal.
    In fact, Miller offers her own experience:
    My digestion is gentler, my sleep is sounder, my energy level is more even. These benefits also seem to have led to improved athletic performance. Since going off gluten, I placed in a race for the first time in my adult life, won a small community biathlon and achieved a personal best in a 5K run. Most important, I felt good while doing it.
    However, there is just no research that documents clear before-and-after changes among athletes who have adopted a gluten-free diet.
    Felicia Stoler, a nutritionist and exercise physiologist, who is president of the Greater New York chapter of the American College of Sports Medicine, says she has yet to see evidence heralding a gluten-free diet for endurance athletes. Until such evidence emerges, says Stoler, many people wise to remain skeptical.
    “If you have nothing wrong with you as far as absorptive disorders, then there’s no benefit by cutting out gluten,” she says. “You have to look at your overall caloric intake needs as an athlete.”
    Source:
    Article from The Washington Post by Anna Medaris Miller, an associate editor of Monitor on Psychology magazine and a health columnist at TheDailyMuse.com.

    Jefferson Adams
    Celiac.com 12/02/2013 - There really hasn't been too much research into gluten levels of products labeled and sold as 'gluten-free in the U.S. A team of researchers recently set out to try to get an idea of gluten levels in food being labeled and sold as 'gluten-free.'
    The good news is that that vast majority of gluten-free foods sampled in their small study were, in fact, gluten-free, and many registered detectable gluten levels far below the 20 ppm allowed by law.
    The research team tested three different samples of 112 separate products, for a total of 336 packages tested. They tested each sample twice, for a total of 672 extractions.
    Of the 112 products tested, 36 products (32%) were certified gluten-free by either the Gluten Free Certification Organization (32 products) or the Celiac Sprue Association (4 products). Only four products (i.e., bread, hot cereal, tortilla, cookie) from three manufacturers tested at or above 20 ppm gluten. Three of these products were not certified gluten-free; one product was certified gluten-free.
    While 9.4% of extractions contained quantifiable gluten, the vast majority of manufacturers are in compliance with the Food and Drug Administration’s gluten-free labeling rule.
    Overall, 97.5 percent of extractions tested below 20 ppm gluten. Of the extractions in compliance, 93% tested below 5 ppm gluten, which is the lower limit of quantification for the assay used.
    Based on the findings of this evaluation, many manufacturers are currently producing food that tests below the 20ppm threshold level of gluten that is currently allowed by the FDA.
    Gluten-free consumers can take comfort in the knowledge that the vast majority of manufacturers who are designating food as gluten-free are complying with the FDA’s labeling rule.
    Source:
    www.medicine.virginia.edu

    Jefferson Adams
    Celiac.com 02/13/2015 - Food intolerance is non-immunological and is often accompanied by gastrointestinal symptoms. 
    What can a review of scientific literature teach us about the causes, diagnosis, mechanisms and clinical evidence regarding food intolerance and gastrointestinal symptoms? Researcher M. C. E. Lomer recently set out to critically analyze the scientific literature related to etiology, diagnosis, mechanisms and clinical evidence as it relates to food intolerance.
    To do so, Lomer searched Pubmed, Embase and Scopus for the terms and variants of food intolerance, lactose, FODMAP, gluten, food chemicals. He restricted his search to human studies published in English. Lomer also conducted a physical search for references to these terms from relevant papers and appropriate studies.
    By Lomer’s assessment, food intolerance affects 15–20% of the population and may be due to pharmacological effects of food ingredients, non-celiac gluten sensitivity or defects in enzyme and transport.
    One area researchers now have a bit more solid scientific data about is the role of short-chain fermentable carbohydrates (FODMAPs) in causing gastrointestinal food intolerance. Food exclusion followed by gradual food reintroduction is the best way to diagnose such food intolerance, and to relieve symptoms.
    There is increasing evidence to support the use of a low FODMAP diet to manage gastrointestinal symptoms in cases of suspected food intolerance. A low FODMAP diet is effective, but changes gastrointestinal microbiota, so reintroducing FODMAPs to the point of tolerance is part of the overall management strategy.
    Exclusionary diets should be as brief as possible. They should be just long enough to induce symptom improvement. They should then be followed by gradual food reintroduction to establish individual tolerance.
    This will help to increase dietary variety, ensure nutritional adequacy and minimize impact on the gastrointestinal microbiota.
    Source:
    Alimentary Pharmacology & Therapeutics. Volume 41, Issue 3, pages 262–275, February 2015. DOI: 10.1111/apt.13041 More info on the FODMAP diet from Stanford Univerisity.

  • Recent Articles

    Jefferson Adams
    Celiac.com 06/16/2018 - Summer is the time for chips and salsa. This fresh salsa recipe relies on cabbage, yes, cabbage, as a secret ingredient. The cabbage brings a delicious flavor and helps the salsa hold together nicely for scooping with your favorite chips. The result is a fresh, tasty salsa that goes great with guacamole.
    Ingredients:
    3 cups ripe fresh tomatoes, diced 1 cup shredded green cabbage ½ cup diced yellow onion ¼ cup chopped fresh cilantro 1 jalapeno, seeded 1 Serrano pepper, seeded 2 tablespoons lemon juice 2 tablespoons red wine vinegar 2 garlic cloves, minced salt to taste black pepper, to taste Directions:
    Purée all ingredients together in a blender.
    Cover and refrigerate for at least 1 hour. 
    Adjust seasoning with salt and pepper, as desired. 
    Serve is a bowl with tortilla chips and guacamole.

    Dr. Ron Hoggan, Ed.D.
    Celiac.com 06/15/2018 - There seems to be widespread agreement in the published medical research reports that stuttering is driven by abnormalities in the brain. Sometimes these are the result of brain injuries resulting from a stroke. Other types of brain injuries can also result in stuttering. Patients with Parkinson’s disease who were treated with stimulation of the subthalamic nucleus, an area of the brain that regulates some motor functions, experienced a return or worsening of stuttering that improved when the stimulation was turned off (1). Similarly, stroke has also been reported in association with acquired stuttering (2). While there are some reports of psychological mechanisms underlying stuttering, a majority of reports seem to favor altered brain morphology and/or function as the root of stuttering (3). Reports of structural differences between the brain hemispheres that are absent in those who do not stutter are also common (4). About 5% of children stutter, beginning sometime around age 3, during the phase of speech acquisition. However, about 75% of these cases resolve without intervention, before reaching their teens (5). Some cases of aphasia, a loss of speech production or understanding, have been reported in association with damage or changes to one or more of the language centers of the brain (6). Stuttering may sometimes arise from changes or damage to these same language centers (7). Thus, many stutterers have abnormalities in the same regions of the brain similar to those seen in aphasia.
    So how, you may ask, is all this related to gluten? As a starting point, one report from the medical literature identifies a patient who developed aphasia after admission for severe diarrhea. By the time celiac disease was diagnosed, he had completely lost his faculty of speech. However, his speech and normal bowel function gradually returned after beginning a gluten free diet (8). This finding was so controversial at the time of publication (1988) that the authors chose to remain anonymous. Nonetheless, it is a valuable clue that suggests gluten as a factor in compromised speech production. At about the same time (late 1980’s) reports of connections between untreated celiac disease and seizures/epilepsy were emerging in the medical literature (9).
    With the advent of the Internet a whole new field of anecdotal information was emerging, connecting a variety of neurological symptoms to celiac disease. While many medical practitioners and researchers were casting aspersions on these assertions, a select few chose to explore such claims using scientific research designs and methods. While connections between stuttering and gluten consumption seem to have been overlooked by the medical research community, there is a rich literature on the Internet that cries out for more structured investigation of this connection. Conversely, perhaps a publication bias of the peer review process excludes work that explores this connection.
    Whatever the reason that stuttering has not been reported in the medical literature in association with gluten ingestion, a number of personal disclosures and comments suggesting a connection between gluten and stuttering can be found on the Internet. Abid Hussain, in an article about food allergy and stuttering said: “The most common food allergy prevalent in stutterers is that of gluten which has been found to aggravate the stutter” (10). Similarly, Craig Forsythe posted an article that includes five cases of self-reporting individuals who believe that their stuttering is or was connected to gluten, one of whom also experiences stuttering from foods containing yeast (11). The same site contains one report of a stutterer who has had no relief despite following a gluten free diet for 20 years (11). Another stutterer, Jay88, reports the complete disappearance of her/his stammer on a gluten free diet (12). Doubtless there are many more such anecdotes to be found on the Internet* but we have to question them, exercising more skepticism than we might when reading similar claims in a peer reviewed scientific or medical journal.
    There are many reports in such journals connecting brain and neurological ailments with gluten, so it is not much of a stretch, on that basis alone, to suspect that stuttering may be a symptom of the gluten syndrome. Rodney Ford has even characterized celiac disease as an ailment that may begin through gluten-induced neurological damage (13) and Marios Hadjivassiliou and his group of neurologists and neurological investigators have devoted considerable time and effort to research that reveals gluten as an important factor in a majority of neurological diseases of unknown origin (14) which, as I have pointed out previously, includes most neurological ailments.
    My own experience with stuttering is limited. I stuttered as a child when I became nervous, upset, or self-conscious. Although I have been gluten free for many years, I haven’t noticed any impact on my inclination to stutter when upset. I don’t know if they are related, but I have also had challenges with speaking when distressed and I have noticed a substantial improvement in this area since removing gluten from my diet. Nonetheless, I have long wondered if there is a connection between gluten consumption and stuttering. Having done the research for this article, I would now encourage stutterers to try a gluten free diet for six months to see if it will reduce or eliminate their stutter. Meanwhile, I hope that some investigator out there will research this matter, publish her findings, and start the ball rolling toward getting some definitive answers to this question.
    Sources:
    1. Toft M, Dietrichs E. Aggravated stuttering following subthalamic deep brain stimulation in Parkinson’s disease--two cases. BMC Neurol. 2011 Apr 8;11:44.
    2. Tani T, Sakai Y. Stuttering after right cerebellar infarction: a case study. J Fluency Disord. 2010 Jun;35(2):141-5. Epub 2010 Mar 15.
    3. Lundgren K, Helm-Estabrooks N, Klein R. Stuttering Following Acquired Brain Damage: A Review of the Literature. J Neurolinguistics. 2010 Sep 1;23(5):447-454.
    4. Jäncke L, Hänggi J, Steinmetz H. Morphological brain differences between adult stutterers and non-stutterers. BMC Neurol. 2004 Dec 10;4(1):23.
    5. Kell CA, Neumann K, von Kriegstein K, Posenenske C, von Gudenberg AW, Euler H, Giraud AL. How the brain repairs stuttering. Brain. 2009 Oct;132(Pt 10):2747-60. Epub 2009 Aug 26.
    6. Galantucci S, Tartaglia MC, Wilson SM, Henry ML, Filippi M, Agosta F, Dronkers NF, Henry RG, Ogar JM, Miller BL, Gorno-Tempini ML. White matter damage in primary progressive aphasias: a diffusion tensor tractography study. Brain. 2011 Jun 11.
    7. Lundgren K, Helm-Estabrooks N, Klein R. Stuttering Following Acquired Brain Damage: A Review of the Literature. J Neurolinguistics. 2010 Sep 1;23(5):447-454.
    8. [No authors listed] Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 43-1988. A 52-year-old man with persistent watery diarrhea and aphasia. N Engl J Med. 1988 Oct 27;319(17):1139-48
    9. Molteni N, Bardella MT, Baldassarri AR, Bianchi PA. Celiac disease associated with epilepsy and intracranial calcifications: report of two patients. Am J Gastroenterol. 1988 Sep;83(9):992-4.
    10. http://ezinearticles.com/?Food-Allergy-and-Stuttering-Link&id=1235725 
    11. http://www.craig.copperleife.com/health/stuttering_allergies.htm 
    12. https://www.celiac.com/forums/topic/73362-any-help-is-appreciated/
    13. Ford RP. The gluten syndrome: a neurological disease. Med Hypotheses. 2009 Sep;73(3):438-40. Epub 2009 Apr 29.
    14. Hadjivassiliou M, Gibson A, Davies-Jones GA, Lobo AJ, Stephenson TJ, Milford-Ward A. Does cryptic gluten sensitivity play a part in neurological illness? Lancet. 1996 Feb 10;347(8998):369-71.

    Jefferson Adams
    Celiac.com 06/14/2018 - Refractory celiac disease type II (RCDII) is a rare complication of celiac disease that has high death rates. To diagnose RCDII, doctors identify a clonal population of phenotypically aberrant intraepithelial lymphocytes (IELs). 
    However, researchers really don’t have much data regarding the frequency and significance of clonal T cell receptor (TCR) gene rearrangements (TCR-GRs) in small bowel (SB) biopsies of patients without RCDII. Such data could provide useful comparison information for patients with RCDII, among other things.
    To that end, a research team recently set out to try to get some information about the frequency and importance of clonal T cell receptor (TCR) gene rearrangements (TCR-GRs) in small bowel (SB) biopsies of patients without RCDII. The research team included Shafinaz Hussein, Tatyana Gindin, Stephen M Lagana, Carolina Arguelles-Grande, Suneeta Krishnareddy, Bachir Alobeid, Suzanne K Lewis, Mahesh M Mansukhani, Peter H R Green, and Govind Bhagat.
    They are variously affiliated with the Department of Pathology and Cell Biology, and the Department of Medicine at the Celiac Disease Center, New York Presbyterian Hospital/Columbia University Medical Center, New York, USA. Their team analyzed results of TCR-GR analyses performed on SB biopsies at our institution over a 3-year period, which were obtained from eight active celiac disease, 172 celiac disease on gluten-free diet, 33 RCDI, and three RCDII patients and 14 patients without celiac disease. 
    Clonal TCR-GRs are not infrequent in cases lacking features of RCDII, while PCPs are frequent in all disease phases. TCR-GR results should be assessed in conjunction with immunophenotypic, histological and clinical findings for appropriate diagnosis and classification of RCD.
    The team divided the TCR-GR patterns into clonal, polyclonal and prominent clonal peaks (PCPs), and correlated these patterns with clinical and pathological features. In all, they detected clonal TCR-GR products in biopsies from 67% of patients with RCDII, 17% of patients with RCDI and 6% of patients with gluten-free diet. They found PCPs in all disease phases, but saw no significant difference in the TCR-GR patterns between the non-RCDII disease categories (p=0.39). 
    They also noted a higher frequency of surface CD3(−) IELs in cases with clonal TCR-GR, but the PCP pattern showed no associations with any clinical or pathological feature. 
    Repeat biopsy showed that the clonal or PCP pattern persisted for up to 2 years with no evidence of RCDII. The study indicates that better understanding of clonal T cell receptor gene rearrangements may help researchers improve refractory celiac diagnosis. 
    Source:
    Journal of Clinical Pathologyhttp://dx.doi.org/10.1136/jclinpath-2018-205023

    Jefferson Adams
    Celiac.com 06/13/2018 - There have been numerous reports that olmesartan, aka Benicar, seems to trigger sprue‐like enteropathy in many patients, but so far, studies have produced mixed results, and there really hasn’t been a rigorous study of the issue. A team of researchers recently set out to assess whether olmesartan is associated with a higher rate of enteropathy compared with other angiotensin II receptor blockers (ARBs).
    The research team included Y.‐H. Dong; Y. Jin; TN Tsacogianis; M He; PH Hsieh; and JJ Gagne. They are variously affiliated with the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School in Boston, MA, USA; the Faculty of Pharmacy, School of Pharmaceutical Science at National Yang‐Ming University in Taipei, Taiwan; and the Department of Hepato‐Gastroenterology, Chi Mei Medical Center in Tainan, Taiwan.
    To get solid data on the issue, the team conducted a cohort study among ARB initiators in 5 US claims databases covering numerous health insurers. They used Cox regression models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for enteropathy‐related outcomes, including celiac disease, malabsorption, concomitant diagnoses of diarrhea and weight loss, and non‐infectious enteropathy. In all, they found nearly two million eligible patients. 
    They then assessed those patients and compared the results for olmesartan initiators to initiators of other ARBs after propensity score (PS) matching. They found unadjusted incidence rates of 0.82, 1.41, 1.66 and 29.20 per 1,000 person‐years for celiac disease, malabsorption, concomitant diagnoses of diarrhea and weight loss, and non‐infectious enteropathy respectively. 
    After PS matching comparing olmesartan to other ARBs, hazard ratios were 1.21 (95% CI, 1.05‐1.40), 1.00 (95% CI, 0.88‐1.13), 1.22 (95% CI, 1.10‐1.36) and 1.04 (95% CI, 1.01‐1.07) for each outcome. Patients aged 65 years and older showed greater hazard ratios for celiac disease, as did patients receiving treatment for more than 1 year, and patients receiving higher cumulative olmesartan doses.
    This is the first comprehensive multi‐database study to document a higher rate of enteropathy in olmesartan initiators as compared to initiators of other ARBs, though absolute rates were low for both groups.
    Source:
    Alimentary Pharmacology & Therapeutics

    Jefferson Adams
    Celiac.com 06/12/2018 - A life-long gluten-free diet is the only proven treatment for celiac disease. However, current methods for assessing gluten-free diet compliance are lack the sensitivity to detect occasional dietary transgressions that may cause gut mucosal damage. So, basically, there’s currently no good way to tell if celiac patients are suffering gut damage from low-level gluten contamination.
    A team of researchers recently set out to develop a method to determine gluten intake and monitor gluten-free dietary compliance in patients with celiac disease, and to determine its correlation with mucosal damage. The research team included ML Moreno, Á Cebolla, A Muñoz-Suano, C Carrillo-Carrion, I Comino, Á Pizarro, F León, A Rodríguez-Herrera, and C Sousa. They are variously affiliated with Facultad de Farmacia, Departamento de Microbiología y Parasitología, Universidad de Sevilla, Sevilla, Spain; Biomedal S.L., Sevilla, Spain; Unidad Clínica de Aparato Digestivo, Hospital Universitario Virgen del Rocío, Sevilla, Spain; Celimmune, Bethesda, Maryland, USA; and the Unidad de Gastroenterología y Nutrición, Instituto Hispalense de Pediatría, Sevilla, Spain.
    For their study, the team collected urine samples from 76 healthy subjects and 58 patients with celiac disease subjected to different gluten dietary conditions. To quantify gluten immunogenic peptides in solid-phase extracted urines, the team used a lateral flow test (LFT) with the highly sensitive and specific G12 monoclonal antibody for the most dominant GIPs and an LFT reader. 
    They detected GIPs in concentrated urines from healthy individuals previously subjected to gluten-free diet as early as 4-6 h after single gluten intake, and for 1-2 days afterward. The urine test showed gluten ingestion in about 50% of patients. Biopsy analysis showed that nearly 9 out of 10 celiac patients with no villous atrophy had no detectable GIP in urine, while all patients with quantifiable GIP in urine showed signs of gut damage.
    The ability to use GIP in urine to reveal gluten consumption will likely help lead to new and non-invasive methods for monitoring gluten-free diet compliance. The test is sensitive, specific and simple enough for clinical monitoring of celiac patients, as well as for basic and clinical research applications including drug development.
    Source:
    Gut. 2017 Feb;66(2):250-257.  doi: 10.1136/gutjnl-2015-310148.